Burger line Burger line Burger line
Logo Logo Logo
Burger line Burger line Burger line
Sign in
Sign in

Eli Lilly to sell low blood sugar drug to Amphastar for around $1 billion

Eli Lilly to sell low blood sugar drug to Amphastar for around $1 billion

Amphastar Pharmaceuticals will buy Baqsimi from Eli Lilly and Co in a deal worth up to $1.08 billion as it aims to boost its portfolio of low blood sugar drugs, the two companies said on Monday.

Amphastar will pay $500 million at closing and another $125 million in cash after one year under the deal.

BAQSIMI is the first and only dry nasal spray that can treat low blood sugar emergencies. It is a form of glucagon given as a puff in the nose.

Eli Lilly is also eligible to receive milestone payments of up to $450 million based on sales of Baqsimi, the only nasally administered drug to treat severely low blood sugar, or hypoglycemia, in people with diabetes.

Severe hypoglycemia is characterized by altered mental or physical functioning, which if untreated, can lead to loss of consciousness, seizure, coma and even death.

Launched in 2019, Baqsimi saw worldwide sales worth $139.3 million in 2022, the companies said.

Lilly had acquired Baqsimi from Locemia Solutions in 2015. The drug has an active compound glucagon, a form of a hormone produced in the pancreas that stimulates glucose production.

Amphastar plans to provide dedicated commercial investment for Baqsimi.

The company had received the U.S. Food and Drug Administration’s approval for the first generic version of glucagon injection in 2020.

Other drugs that are used to treat low blood sugar in diabetes patients include Novo Nordisk’s Zegalogue and GlucaGen and Xeris Pharmaceuticals’ Gvoke HypoPen. 

Published Apr 24, 2023


0
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote

We use "cookies*  to ensure the functionality of our website, recognise your browser or device, learn more about your interests, and provide you with essential features and services and for additional purposes, including:

Recognising you when you sign-in to use our services. This allows us to provide you with product recommendations, display personalised content, and provide other customised features and services.
Keeping track of your specified preferences. You may set your preferences through Your Account..
Keeping track of items stored in your shopping basket and personal cabinet.
Conducting research and diagnostics to improve ChemDiv’s content, products, and services.
Delivering content, including ads, relevant to your interests on ChemDiv’s site
Reporting. This allows us to measure and analyse the performance of our services.

By  cookies you give consent to the processing of your personal data, including transfer to third parties. Further information can be found in our privacy policy.

Accept all cookies